{"filing":{"accession_number":"0001193125-26-292567","cik":"0001768446","ticker":"CLYM","company_name":"Climb Bio, Inc.","form":"8-K","filing_date":"2026-07-01","report_date":null,"primary_document":"d61061d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526292567/d61061d8k.htm"},"events":[{"id":15503,"run_id":13830,"accession_number":"0001193125-26-292567","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The filing discloses both a director resignation (Andrew Levin) and the election of a new director (Breanna O'Reilly, Ph.D.) on the same date. While both events are present, the principal action emphasized in the disclosure is Dr. O'Reilly's election to the Board effective immediately, with detailed information about her compensation package (70,284 option grant at $13.36/share, $40,000 annual cash retainer, and future equity grants). The appointment is the forward-looking event and receives substantially more disclosure than the departure.","company_name":"Climb Bio, Inc.","ticker":"CLYM","filing_date":"2026-07-01","form":"8-K","submitted_at":null,"items":[{"id":13308,"accession_number":"0001193125-26-292567","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses both a director resignation (Andrew Levin) and the election of a new director (Breanna O'Reilly, Ph.D.) on the same date. While both events are present, the principal action emphasized in the disclosure is Dr. O'Reilly's election to the Board effective immediately, with detailed information about her compensation package (70,284 option grant at $13.36/share, $40,000 annual cash retainer, and future equity grants). The appointment is the forward-looking event and receives substantially more disclosure than the departure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:17:29.663238+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13308,"accession_number":"0001193125-26-292567","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses both a director resignation (Andrew Levin) and the election of a new director (Breanna O'Reilly, Ph.D.) on the same date. While both events are present, the principal action emphasized in the disclosure is Dr. O'Reilly's election to the Board effective immediately, with detailed information about her compensation package (70,284 option grant at $13.36/share, $40,000 annual cash retainer, and future equity grants). The appointment is the forward-looking event and receives substantially more disclosure than the departure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:17:29.663238+00:00","company_name":"Climb Bio, Inc.","ticker":"CLYM","filing_date":"2026-07-01"}]}